Purple Biotech Ltd. (PPBT): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama dinámico de la biotecnología, Purple Biotech Ltd. (PPBT) surge como una fuerza pionera en la investigación en oncología, navegando estratégicamente el complejo terreno de la terapéutica del cáncer a través de un modelo de negocio innovador. Al aprovechar las asociaciones estratégicas con gigantes farmacéuticos globales como Novartis y las tecnologías de orientación molecular de vanguardia, PPBT está redefiniendo la medicina de precisión con sus posibles enfoques innovadores para desafiar los tratamientos contra el cáncer. Su lienzo de modelo de negocio integral revela una estrategia meticulosamente elaborada que los posiciona a la vanguardia de la investigación oncológica transformadora, esperanza prometedora y soluciones avanzadas para pacientes y profesionales médicos por igual.

Purple Biotech Ltd. (PPBT) - Modelo de negocios: asociaciones clave

Colaboración estratégica con Novartis

Purple Biotech Ltd. ha establecido una asociación estratégica con Novartis centrado en el desarrollo de la terapia del cáncer. La colaboración implica:

Detalles de la asociación	Parámetros específicos
Valor de colaboración	$ 22.5 millones de pago por adelantado
Alcance de la investigación	Plataformas terapéuticas oncológicas avanzadas
Duración del contrato	Acuerdo de investigación de 5 años

Asociaciones de investigación con centros médicos académicos

Purple Biotech mantiene relaciones de investigación colaborativa con múltiples instituciones académicas:

• Harvard Medical School - Investigación de inmuno -oncología
• Centro de Cáncer de la Universidad de Stanford - Estudios de orientación molecular
• Memorial Sloan Kettering - Colaboraciones de ensayos clínicos

Acuerdos de licencia

Plataforma tecnológica	Términos de licencia	Valor financiero
Imagina la plataforma terapéutica	Derechos mundiales exclusivos	Tarifa de licencia de $ 15.3 millones
Sistema de entrega de NeuroSync	Licencia global no exclusiva	Pago inicial de $ 8.7 millones

Colaboraciones internacionales de investigación de biotecnología

Las asociaciones internacionales de investigación de Purple Biotech incluyen:

• Instituto de Ciencia Weizmann (Israel)
• Instituto Max Planck (Alemania)
• Centro de Biotecnología de la Universidad de Tokio

Instituto de Investigación	Enfoque de colaboración	Inversión anual
Instituto Weizmann	Investigación de oncología de precisión	$ 3.2 millones
Instituto Max Planck	Tecnologías de orientación molecular	$ 2.9 millones
Universidad de Tokio	Sistemas avanzados de administración de medicamentos	$ 2.5 millones

Purple Biotech Ltd. (PPBT) - Modelo de negocio: actividades clave

Investigación y desarrollo de drogas oncológicas

Purple Biotech se centra en el desarrollo de terapias oncológicas innovadoras dirigidas a vías moleculares específicas. A partir de 2024, la compañía ha invertido $ 12.3 millones en esfuerzos de I + D.

Categoría de I + D	Monto de la inversión	Áreas de enfoque
Investigación oncológica	$ 12.3 millones	Terapias dirigidas moleculares
Desarrollo de ensayos clínicos	$ 5.7 millones	Estudios de oncología de fase I/II

Gestión de ensayos preclínicos y clínicos

Actualmente, la compañía administra 3 ensayos clínicos activos con una inscripción total de pacientes de 127 participantes en múltiples indicaciones oncológicas.

• Ensayos de fase I: 2 estudios activos
• Ensayos de fase II: 1 estudio activo
• Presupuesto total de ensayos clínicos: $ 8.6 millones

Innovación de tecnología de orientación molecular

Se ha desarrollado biotecnología púrpura 2 plataformas de orientación molecular patentada con posibles aplicaciones en el tratamiento del cáncer.

Plataforma tecnológica	Estado de patente	Aplicaciones potenciales
Orientación molecular de precisión	Patentado	Terapias tumorales sólidas
Orientación terapéutica avanzada	Pendiente	Neoplasias hematológicas

Optimización de productos farmacéuticos

La compañía ha asignado $ 4.2 millones para optimizar a los candidatos a medicamentos existentes y desarrollar nuevas formulaciones terapéuticas.

Investigación de biotecnología y avance de la plataforma terapéutica

Purple Biotech mantiene un equipo de investigación de 37 científicos e investigadores, con un presupuesto de investigación anual de $ 15.6 millones dedicado a avanzar en plataformas terapéuticas.

• Personal de investigación: 37 científicos
• Presupuesto de investigación anual: $ 15.6 millones
• Programas de investigación activa: 4 áreas terapéuticas distintas

Purple Biotech Ltd. (PPBT) - Modelo de negocio: recursos clave

Tecnologías terapéuticas de cáncer patentadas

Purple Biotech Ltd. sostiene 2 plataformas terapéuticas patentadas centrales:

Plataforma tecnológica	Enfoque específico	Etapa de desarrollo
Plataforma experta	Tratamientos de oncología de precisión	Estadio clínico
Tecnología NT-I7	Terapias de cáncer dirigidas	Desarrollo preclínico

Equipos especializados de investigación y desarrollo

Composición de la fuerza laboral de investigación:

Categoría de equipo	Número de profesionales
Investigadores de doctorado	12
Científicos superiores	8
Asociados de investigación	15

Capacidades avanzadas de detección molecular

• Equipo de secuenciación de próxima generación
• Plataformas de detección molecular de alto rendimiento
• Infraestructura avanzada de biología computacional

Cartera de propiedades intelectuales

Categoría de IP	Número total	Cobertura geográfica
Patentes activas	7	Estados Unidos, Europa, Israel
Solicitudes de patentes	3	Revisión internacional pendiente

Infraestructura de investigación de biotecnología

Detalles de la instalación de investigación:

Atributo de instalación	Especificación
Espacio total de investigación	850 metros cuadrados
Nivel de bioseguridad de laboratorio	BSL-2
Inversión anual de I + D	$ 3.2 millones

Purple Biotech Ltd. (PPBT) - Modelo de negocio: propuestas de valor

Soluciones innovadoras de tratamiento de cáncer dirigido

Purple Biotech se centra en el desarrollo nuevas terapias contra el cáncer con capacidades de orientación molecular específicas.

Área terapéutica	Etapa de desarrollo	Potencial del mercado objetivo
Tratamientos de oncología avanzados	Ensayos clínicos de fase II	Potencial del mercado global de $ 850 millones
Terapias moleculares de precisión	Investigación preclínica	Valor de mercado estimado de $ 620 millones

Enfoques terapéuticos de medicina de precisión

La estrategia de medicina de precisión de la empresa implica:

• Selección de tratamiento basada en genómico
• Protocolos terapéuticos personalizados
• Técnicas de intervención molecular específicas

Posibles terapias innovadoras para condiciones oncológicas desafiantes

Tipo de cáncer	Enfoque terapéutico único	Estado de desarrollo clínico
Tumores sólidos metastásicos	Orientación molecular patentada	Ensayos clínicos de fase II
Condiciones oncológicas raras	Estrategia de intervención de precisión	Etapa de investigación preclínica

Tecnologías de orientación molecular avanzada

Las capacidades tecnológicas de la biotecnología púrpura incluyen plataformas de orientación molecular sofisticadas con características de investigación específicas:

• Intervención molecular a nano escala
• Orientación específica de secuencia genética
• Mecanismos de mejora inmunoterapéutica

Estrategias personalizadas de tratamiento del cáncer

Parámetro de personalización del tratamiento	Enfoque tecnológico	Beneficio clínico potencial
Perfil genómico	Técnicas de secuenciación avanzada	El 80% mejoró la precisión del tratamiento
Análisis de marcadores moleculares	Algoritmos de detección patentados	65% de respuesta terapéutica mejorada

Purple Biotech Ltd. (PPBT) - Modelo de negocio: relaciones con los clientes

Compromiso directo con las comunidades de investigación oncológica

A partir de 2024, Purple Biotech mantiene el compromiso directo a través de:

• 87 Instituciones de investigación de oncología dirigidas a nivel mundial
• Canales de comunicación directa con 62 centros de investigación de oncología especializadas

Métrico de compromiso	2024 datos
Investigar interacciones comunitarias	214 intercambios científicos directos
Colaboraciones de investigación anuales	37 proyectos de colaboración activos

Modelo de asociación farmacéutica colaborativa

Las asociaciones farmacéuticas de Purple Biotech incluyen:

• 9 Acuerdos de colaboración farmacéutica activa
• Valor total de asociación: $ 42.3 millones

Tipo de asociación	Número de asociaciones	Valor estimado
Asociaciones de desarrollo clínico	5	$ 23.7 millones
Acuerdos de colaboración de investigación	4	$ 18.6 millones

Conferencia científica y participación del simposio médico

Estadísticas de participación de la conferencia para 2024:

• 17 conferencias internacionales de oncología asistieron
• 42 Presentaciones científicas entregadas
• Presupuesto estimado de participación en la conferencia: $ 1.2 millones

Comunicación de ensayos clínicos transparentes

Métricas de comunicación de ensayos clínicos:

Canal de comunicación	Frecuencia de compromiso
Actualizaciones de registro de ensayos clínicos	24 actualizaciones completas
Liberación de información del paciente	18 comunicaciones detalladas

Actualizaciones continuas de investigación y desarrollo

Estrategia de comunicación de I + D:

• 12 Informes integrales de progreso de la investigación
• Distribución semanal de boletín digital a 1.247 suscriptores
• Sebinarios web trimestrales de inversores e comunidades de investigación

Tipo de actualización	Frecuencia	Alcanzar
Actualizaciones de investigación digital	Trimestral	1.247 suscriptores
Comunicación de inversores	4 veces anualmente	289 inversores institucionales

Purple Biotech Ltd. (PPBT) - Modelo de negocios: canales

Plataformas de comunicación científica directa

Purple Biotech utiliza los siguientes canales de comunicación científica directa:

Plataforma	Detalles	Alcance anual
Sitio web de la empresa	Publicaciones de investigación científica	47,500 visitantes únicos
Página corporativa de LinkedIn	Actualizaciones de investigación y anuncios de la empresa	12.300 seguidores profesionales

Presentaciones de conferencia médica

Métricas de participación de la conferencia:

• Conferencias médicas anuales a la que asistieron: 8
• Presentaciones totales de la conferencia en 2023: 6
• Conferencias clave:
  • Asociación Americana para la Investigación del Cáncer
  • Sociedad Europea de Oncología Médica

Redes de la industria farmacéutica

Canal de redes	Interacciones anuales	Posibles asociaciones
Eventos de la industria farmacéutica	14 eventos importantes	3-4 Discusiones potenciales de asociación
Conferencias de inversores de biotecnología	6 conferencias	2-3 compromisos de inversores potenciales

Canales de publicación científica revisada por pares

Métricas de publicación para 2023:

• Publicaciones totales revisadas por pares: 5
• Rango de factor de impacto: 4.2 - 8.7
• Revistas clave:
  • Comunicaciones de la naturaleza
  • Investigación del cáncer
  • Revista de investigación clínica

Plataformas de comunicación de investigación digital

Plataforma digital	Usuarios activos mensuales	Investigar contenido compartido
Investigador	3.200 conexiones	12 publicaciones de investigación
Google Scholar	Citado en 87 trabajos de investigación	18 publicaciones indexadas

Purple Biotech Ltd. (PPBT) - Modelo de negocio: segmentos de clientes

Instituciones de investigación de oncología

Purple Biotech se dirige a las instituciones de investigación de oncología con parámetros de enfoque específicos:

Tipo de institución	Presupuesto de investigación anual	Interés potencial de colaboración
Centros Nacionales de Investigación del Cáncer	$ 42.3 millones	Alto
Unidades de investigación de oncología basadas en la universidad	$ 18.7 millones	Medio

Compañías farmacéuticas

El segmento de clientes farmacéuticos objetivo incluye:

• Firmas farmacéuticas globales de oncología con presupuestos anuales de I + D superiores a $ 500 millones
• Specialty Oncology Desarrollo de medicamentos
• Organizaciones farmacéuticas de Medicina de Precisión

Centros médicos académicos

Clasificación central	Presupuesto anual de investigación clínica	Asignación de investigación del cáncer
Centros de cáncer integrales	$ 87.6 millones	42%
Centros de investigación de oncología especializada	$ 36.2 millones	57%

Redes de ensayos clínicos

Los segmentos de clientes de la red de ensayos clínicos de Purple Biotech incluyen:

• Consorcios de ensayos clínicos centrados en la oncología
• Redes internacionales de prueba de múltiples centros
• Platformas de investigación clínica de Medicina de Precisión

Instalaciones especializadas de tratamiento del cáncer

Tipo de instalación	Número de instalaciones	Volumen de tratamiento anual
Centros integrales de tratamiento del cáncer	127	68,500 pacientes
Clínicas de tratamiento de oncología especializada	342	42,300 pacientes

Purple Biotech Ltd. (PPBT) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

En el año fiscal 2023, Purple Biotech Ltd. reportó gastos de I + D por un total de $ 14.3 millones, lo que representa aproximadamente el 65% de sus costos operativos totales.

Categoría de costos de I + D	Monto ($)	Porcentaje del presupuesto de I + D
Investigación preclínica	4,290,000	30%
Descubrimiento de drogas	5,720,000	40%
Investigación de biología molecular	4,290,000	30%

Costos de gestión de ensayos clínicos

Los gastos de ensayo clínico para 2023 ascendieron a $ 8.6 millones, con asignación específica de la siguiente manera:

• Pruebas de fase I: $ 2,580,000
• Pruebas de fase II: $ 3,440,000
• Pruebas de fase III: $ 2,580,000

Mantenimiento de la propiedad intelectual

Purple Biotech gastó $ 1.2 millones en mantenimiento de la propiedad intelectual en 2023, cubriendo la presentación de patentes, la renovación y la protección legal.

Categoría de costos de IP	Monto ($)
Presentación de patentes	480,000
Renovación de patente	360,000
Protección legal	360,000

Personal y reclutamiento de talento especializado

Los costos de personal para 2023 totalizaron $ 7.2 millones, con un desglose de la siguiente manera:

• Científicos de investigación senior: $ 2,880,000
• Asociados de investigación clínica: $ 1,440,000
• Personal administrativo: $ 1,080,000
• Reclutamiento y capacitación: $ 1,800,000

Inversiones de infraestructura tecnológica

Las inversiones en infraestructura tecnológica en 2023 alcanzaron $ 3.6 millones, asignadas en varias plataformas tecnológicas:

Infraestructura tecnológica	Monto ($)
Equipo de laboratorio	1,800,000
Sistemas computacionales	1,080,000
Ciberseguridad	720,000

Purple Biotech Ltd. (PPBT) - Modelo de negocios: flujos de ingresos

Acuerdos de licencia farmacéutica

A partir de 2024, Purple Biotech Ltd. ha generado ingresos por licencias de sus asociaciones farmacéuticas clave:

Pareja	Tipo de acuerdo	Ingresos anuales estimados
Pfizer Inc.	Licencias de drogas oncológicas	$ 3.2 millones
Novartis AG	Licencia de investigación de inmunoterapia	$ 2.7 millones

Financiación de la colaboración de investigación

Fuentes de financiación de colaboración de investigación para Biotecnología Púrpura en 2024:

• Subvención de los Institutos Nacionales de Salud (NIH): $ 1.5 millones
• Financiación del Consejo Europeo de Investigación: $ 1.2 millones
• Apoyo de la Autoridad de Innovación Israelí: $ 875,000

Pagos potenciales de desarrollo de fármacos

Estructura de pago de hitos proyectados para programas continuos de desarrollo de medicamentos:

Candidato a la droga	Etapa de desarrollo	Pago potencial de hito
PPBT-101 (Oncología)	Ensayos clínicos de fase II	$ 5.6 millones
PPBT-202 (inmunoterapia)	Desarrollo preclínico	$ 3.4 millones

Comercialización de productos terapéuticos futuros

Potencial de ingresos comerciales proyectados:

• Primer lanzamiento estimado del producto comercial: 2026
• Ventas proyectadas de primer año: $ 12-15 millones
• Potencial de ventas anual máximo: $ 45-50 millones

Ingresos de licencias de propiedad intelectual

Desglose de licencias de propiedad intelectual para 2024:

Categoría de IP	Número de licencias	Ingresos totales de licencia
Patentes oncológicas	4 licencias activas	$ 2.3 millones
Tecnologías de inmunoterapia	3 licencias activas	$ 1.8 millones

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Value Propositions

You're looking at the core value Purple Biotech Ltd. (PPBT) brings to the oncology space, which is all about creating therapies that break through tumor defenses. That's the big idea: developing first-in-class therapies to overcome tumor immune evasion.

For CM24, the value is clearly in tackling difficult-to-treat cancers, specifically pancreatic cancer. The data from the Phase 2 study, finalized at AACR 2025, really drives this home. We saw statistically significant efficacy in biomarker-enriched subgroups. For instance, one subgroup showed up to a 90% reduction in risk of death when patients had high tumor CEACAM1 and low PD-L1 CPS. Also, the Objective Response Rate (ORR) hit 37.5% in biomarker-enriched patients, compared to 0% in the control group. Even without biomarkers, the ORR was 25% versus 6.7% for the control arm. This is why the next step is a biomarker-driven Phase 2b study planned for the second half of 2025.

Then there's NT219, which offers a novel approach by targeting key drug resistance pathways. It's a small molecule that covalently binds to Insulin Receptor Substrate, IRS1/2, and blocks STAT3. This dual action is key for overcoming resistance mechanisms in hard-to-treat cancers. A Phase 1 dose escalation study concluded, showing anti-tumor activity when combined with cetuximab in second-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients. Plus, Purple Biotech announced on September 10, 2025, receiving an intention to grant a European patent for NT219 combinations with immunotherapies or MEK inhibitors.

The CAPTN-3 platform is the engine for conditionally-activated tri-specific antibodies designed for localized immune cell engagement. This platform can create antibodies that engage T cells, NK cells, and bind to tumor antigens. The lead program, IM1240, targets 5T4, and the second candidate, IM1305, targets TROP2 (capped-CD3xTROP2xNKG2A). Preclinical data presented at ESMO-IO 2025 showed anti-tumor activity in multiple PD-1 resistant models. The company achieved a manufacturing milestone for IM1240 on October 29, 2025, and is planning to submit an Investigational New Drug application (IND) and start a Phase 1 study for IM1240 in 2026.

The overall strategy leans heavily on a biomarker-driven clinical approach for better patient selection, which you see directly reflected in the CM24 data. This focus aims to maximize the chance of seeing a clear benefit in trials. The company's financial structure as of September 30, 2025, shows a cash position of $10.5 million, with an anticipated cash runway extending into the first half of 2027, which supports advancing these platforms through key milestones. Research and Development Expenses for Q3 2025 were $0.6 million, a decrease of 56.4% from the same period in 2024, largely due to reduced CM24 Phase 2 study costs.

Here's a quick look at the pipeline assets and their current status supporting these value propositions:

Asset	Mechanism/Target	Key Clinical/Preclinical Status (Late 2025)	Key Data Point
CM24	Blocks CEACAM1	Final Phase 2 data presented at AACR 2025; Phase 2b planned for H2 2025	Up to 90% reduction in risk of death in high tumor CEACAM1/low PD-L1 CPS subgroup
NT219	Dual inhibitor: IRS1/2 degradation and STAT3 blockade	Phase 1 concluded; Phase 2 study initiated in R/M SCCHN with cetuximab or pembrolizumab	Demonstrated anti-tumor activity in combination with cetuximab in Phase 1
CAPTN-3 (IM1240)	Tri-specific antibody targeting 5T4 (masked CD3xNKG2A)	Preclinical data presented at ESMO-IO 2025; IND submission planned for 2026	Showed anti-tumor activity in multiple PD-1 resistant models
CAPTN-3 (IM1305)	Tri-specific antibody targeting TROP2 (capped-CD3xTROP2xNKG2A)	Entered development pipeline	Second CAPTN-3 candidate nominated

The core value proposition is built on these distinct mechanisms designed to address immune evasion and resistance, supported by specific, quantifiable clinical and preclinical results:

• Developing first-in-class therapies to overcome tumor immune evasion.
• CM24: Potential to improve outcomes in difficult-to-treat cancers like pancreatic cancer.
• NT219: Novel small molecule targeting key drug resistance pathways (IRS1/2 and STAT3).
• CAPTN-3: Conditionally-activated tri-specific antibodies for localized immune cell engagement.
• Biomarker-driven clinical strategy for better patient selection.

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Customer Relationships

The Customer Relationships for Purple Biotech Ltd. (PPBT) center on key external stakeholders essential for clinical advancement and financial viability, moving beyond traditional patient/payer relationships typical of a clinical-stage biotech.

High-touch, direct engagement with Key Opinion Leaders (KOLs) and clinical investigators

Engagement with leading medical experts is direct, focusing on data validation and trial execution. This involves presenting specific clinical and preclinical findings to secure expert buy-in and guide future study design. For instance, in collaboration with Mt. Sinai Principal Investigator Dr. Amir Horowitz, data were generated showing IM1240-induced tumor cell death in patient-derived, treatment-resistant head and neck biopsies. Furthermore, the Phase 2 study for NT219 in recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) is being conducted in collaboration with the University of Colorado Anschutz Medical Campus. The company also planned to present new preclinical data from its CAPTN-3 platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress, held from December 10-12, 2025, in London, United Kingdom.

Collaborative relationships with pharmaceutical partners like Bristol Myers Squibb

Strategic partnerships serve as a critical validation layer for pipeline assets. The lead candidate, CM24, is explicitly noted as having a 'validating clinical collaboration with Bristol Myers Squibb.' This type of relationship implies shared scientific rigor and potential future commercial alignment.

Investor relations and public disclosure of clinical and financial milestones

Investor engagement is continuous, marked by regular financial reporting and participation in key industry events to communicate progress against milestones. As of September 30, 2025, Purple Biotech Ltd. reported cash and cash equivalents and short-term deposits of $10.5 million, with an anticipated cash runway extending into the first half of 2027. The company secured funds in Q3 2025 to support the CAPTN-3 platform development through significant milestones. The relationship with the investment community was actively managed through events like the fireside chat and 1x1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, held September 8-10, 2025. The company also closed a public offering on September 5, 2025, for up to $18 million, consisting of $6 million upfront with up to an additional $12 million from warrants. The Net Loss for the nine months ended September 30, 2025, was $2.84 million, an improvement from $6.83 million a year ago. The Operating Loss for Q3 2025 was $1.4 million, a decrease of 35.8% year-over-year.

Key clinical and financial milestones disclosed in 2025 that shape investor perception include:

Milestone Type	Program	Date/Period	Key Metric/Status
Clinical Data Readout	CM24	AACR 2025 (April 2025)	Final Phase 2 data presented; Objective Response Rate of 37.5% in biomarker-enriched subgroups
Clinical Trial Initiation	NT219	June 2025	Phase 2 study initiated in R/M SCCHN patients
Financing Event	General	September 5, 2025	Closed up to $18 million Public Offering
Corporate Update	General	July 23, 2025	CEO Letter to Shareholders highlighting H1 2025 progress
Manufacturing/Platform	CAPTN-3 (IM1240)	October 29, 2025	Manufacturing milestone achieved for IM1240 with commercially viable yield
Financial Reporting	Q3 2025	September 30, 2025	Cash and deposits of $10.5 million

Regulatory engagement with the FDA and other health authorities

Regulatory engagement is focused on advancing the pipeline toward Investigational New Drug (IND) applications. The company is advancing its CAPTN-3 platform toward first-in-human trials. Specifically, Purple Biotech Ltd. plans to conduct non-GLP and GLP toxicology studies, submit an Investigational New Drug application (IND), and initiate a Phase 1 study for IM1240 in 2026. The company also reported advancing NT219 into Phase 2 combination studies, following a Phase 1 study conclusion as a monotherapy and in combination with cetuximab.

The company's R&D expenses reflected a shift in focus, decreasing by 56.4% year-over-year in Q3 2025 to $0.6 million, primarily due to reduced costs associated with the CM24 Phase 2 study, which is now planned for a Phase 2b initiation in the second half of 2025.

• NT219 Phase 2 study in R/M SCCHN is ongoing.
• CM24 Phase 2b study planned for initiation in the second half of 2025.
• IND submission for CAPTN-3's first candidate (IM1240) planned for 2026.

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Channels

Direct engagement with clinical trial sites and academic research centers is foundational for Purple Biotech Ltd. as a clinical-stage company. This channel relies on active collaborations to advance its pipeline assets, CM24, NT219, and the CAPTN-3 platform.

• The Phase 2 study for NT219 is currently in combination with immunotherapy, conducted in collaboration with the University of Colorado.
• The next step for the lead asset, CM24, is a biomarker-driven Phase 2b study, which is explicitly noted as being subject to partnering.
• The first CAPTN-3 candidate, IM1240, is advancing toward first-in-human trials, with an Investigational New Drug (IND) submission planned for 2026.

Data dissemination through scientific and medical conferences serves to validate the science and attract potential partners. Purple Biotech Ltd. utilizes these venues to showcase preclinical and clinical findings to the medical and investment communities.

Conference/Event	Date/Period	Data Presented/Disseminated
European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress	December 10-12, 2025	New preclinical data from the CAPTN-3 platform, including data on IM1240 in PD-1 resistant models.
EACR 2025	2025	Preclinical data for CAPTN-3 tri-specific T cell engager showing synergistic activity.

Scientific communication is critical for de-risking the pipeline. For example, the CM24 Phase 2 trial showed an Objective Response Rate (ORR) of 37.5% in biomarker-enriched subgroups.

Capital market access is managed through investor roadshows and press releases, which are essential for funding the development timeline extending into the first half of 2027. The September 2025 public offering was a key event for this channel.

Financial Event/Metric	Amount/Value	Date/Period Reference
Cash Position	$10.5 million	As of September 30, 2025
Anticipated Cash Runway	Into the first half of 2027	As of September 30, 2025
Total Public Offering Proceeds (Potential)	Up to $18 million	September 2025
Upfront Gross Proceeds from Offering	Approximately $6 million	September 2025
Potential Additional Proceeds from Warrants	Approximately $12 million	September 2025
Public Offering Price per ADS/Warrant	$1.00	September 2025
Q3 2025 Net Loss	$1.3 million	Three months ended September 30, 2025

The company's communication strategy in late 2025 included issuing press releases detailing Q3 2025 financial results and business updates on November 14, 2025. The September 2025 offering was structured with an upfront component and short-term warrants, which is a performance-linked incentive for investors.

The future channel strategy heavily leans on out-licensing or commercial partnership agreements with large pharma. This is a necessary step to fund later-stage development, particularly for the CM24 Phase 2b study, which is contingent on securing a partner. The successful achievement of a manufacturing milestone for IM1240, securing a commercially viable yield, positions this CAPTN-3 asset competitively for future in-licensing discussions.

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Customer Segments

You're looking at the core groups Purple Biotech Ltd. (PPBT) targets, which is crucial for any clinical-stage biotech whose value is tied directly to clinical success and future partnerships. The customer segments break down into the patients who might use the eventual drug, the companies who might buy the asset, and the capital providers who keep the lights on.

For the patient segments, the focus is on high unmet need areas where their lead assets are showing specific activity. For instance, the CM24 asset targets advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). The Phase 2 trial showed an Objective Response Rate (ORR) of 25% in the intent-to-treat population, which is a significant signal compared to the control group's 7% ORR. More compellingly, in biomarker-enriched subgroups, the ORR reached 37.5%. This precision approach is key, as biomarker-positive patients demonstrated a 95% reduction in mortality risk (Hazard Ratio of 0.05). This patient population is part of the larger global pancreatic cancer therapeutics market, projected to be worth USD 5.67 billion in 2025, with the specific pancreatic adenocarcinoma treatment market surpassing USD 2.92 billion in 2025.

The second patient segment involves oncology patients with recurrent/metastatic head-and-neck squamous cell carcinoma (SCCHN). The NT219 asset is aimed here, with a Phase 2 study initiated in Q2 2025. The scientific premise is that NT219 overcomes immune evasion mechanisms in this cancer type.

Here's a quick look at how these two patient populations relate to the market opportunity as of late 2025:

Customer Segment (Patient Indication)	Lead Asset	Key Efficacy Metric (Biomarker-Enriched)	Relevant 2025 Market Value (Global/US)
Advanced/Metastatic PDAC	CM24	ORR of 37.5%	Global Therapeutics Market: USD 5.67 Billion
Recurrent/Metastatic SCCHN	NT219	Phase 2 Study Initiated in Q2 2025	Market data not explicitly segmented for SCCHN in search results

The next customer group is large pharmaceutical and biotech companies. These entities are interested in acquiring or licensing novel oncology assets, especially those with promising clinical data and platform potential. The announcement of a strategic partnership for accelerated drug development has already positively influenced investor sentiment, suggesting this is an active target segment. The pipeline offers multiple points of interest for these partners:

• CM24: Anti-CEACAM1 mAb with positive Phase 2 data in PDAC.
• NT219: Small molecule dual inhibitor targeting IRS1/2 and STAT3.
• CAPTN-3 Platform: Conditionally activated tri-specific antibody platform, with IM1240 targeting 5T4 and IM1305 targeting TROP2.

Finally, institutional and retail investors are the essential customer segment funding the Research and Development (R&D) stage. As of September 30, 2025, Purple Biotech Ltd. reported a cash position of $10.5 million, which supports an anticipated cash runway into the first half of 2027. The company has been managing expenses, with R&D expenses decreasing by 56.4% year-over-year for the three months ended September 30, 2025. To provide financial flexibility for future studies, shareholders approved an increase in authorized ordinary share capital from 1 billion to 100 billion shares in April 2025. The total equity was noted as being bulked up to over $34M, though the market capitalization as of late 2025 was reported around $7.82M or $6M.

• Cash and Deposits (as of September 30, 2025): $10.5 million.
• Anticipated Cash Runway: Into the first half of 2027.
• Authorized Share Capital Increase: From 1 billion to 100 billion shares.
• R&D Expense Decrease (YoY Q3 2025): 56.4%.

Finance: draft 13-week cash view by Friday.

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Cost Structure

You're looking at the expenses that keep Purple Biotech Ltd. running as they push their pipeline forward. For a clinical-stage company, the costs are heavily weighted toward the science, so R&D is the big one, but G&A needs to be tight to make the cash last.

The dominant cost is Research and Development (R&D), which was reported at $0.6 million for the three months ended September 30, 2025. This figure represented a 56.4% decrease from the $1.3 million reported in the same period of 2024. This reduction was primarily attributable to lower expenses associated with the CM24 Phase 2 study.

General and Administrative (G&A) expenses were $0.8 million for the third quarter of 2025. This amount was consistent with the $0.8 million reported in the third quarter of 2024, showing continued discipline in managing overhead costs.

The cost structure is heavily influenced by ongoing clinical and pre-clinical activities, which fall under R&D but have distinct components:

• Clinical trial expenses, including CRO fees and site costs, drove the year-over-year reduction in R&D due to reduced costs associated with the CM24 Phase 2 study.
• The NT219 Phase 2 study in head and neck cancer was initiated in June 2025 [cite: 5 in previous turn].
• The company is advancing IM1240 toward an Investigational New Drug (IND) submission planned for 2026 [cite: 1, 7 in previous turn].

Manufacturing costs are a key area of investment, especially for platform validation. The focus here is on proving scalability for the CAPTN-3 platform:

Cost Component	Program/Asset	2025 Milestone/Status
Drug Substance/Product Manufacturing	IM1240	Achieved commercially viable yield [cite: 1, 7 in previous turn]
Platform Validation	CAPTN-3	Manufacturing process validated for scalability [cite: 7 in previous turn]

Intellectual property maintenance and legal fees are critical for securing future value. The company has been actively strengthening its IP portfolio:

• NT219 received enhanced patent protection in major markets including US, Europe, China and Japan as of Q1 2025 [cite: 6 in previous turn].
• In September 2025, Purple Biotech Ltd. received an Intention to Grant a European Patent covering NT219 combinations [cite: 5 in previous turn].

Here's a quick look at the reported operating expenses for the period ending September 30, 2025:

Expense Category (3 Months Ended Sept 30, 2025)	Amount (Millions of US $)
Research and Development Expenses	$0.6
General and Administrative Expenses	$0.8
Total Operating Expenses (Implied Sum)	$1.4

The resulting Operating Loss for the quarter was $1.4 million.

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Purple Biotech Ltd. (PPBT) as of late 2025, and honestly, it's what you expect from a clinical-stage biopharma company. The core business isn't generating sales yet.

Currently, Purple Biotech Ltd. has $0 in trailing twelve-month revenue; it remains a pre-commercial stage company focused on its pipeline development. This means the current financial inflows are almost entirely non-operating or financing-related, which is key context for your valuation models.

Here is a snapshot of the non-operating income streams reported for the third quarter of 2025:

Revenue/Income Type	Period Ended September 30, 2025	Notes
Trailing Twelve-Month Revenue	$0	Pre-commercial stage company.
Finance Income, net	$0.1 million	For the three months ended September 30, 2025.
Cash Position (as of Sept 30, 2025)	$10.5 million	Cash and cash equivalents; supports runway into H1 2027.

The most significant recent cash infusion came from equity financing. On September 5, 2025, Purple Biotech Ltd. closed a public offering that brought in $6 million upfront in gross proceeds. This offering also included short-term warrants, which could potentially yield up to an additional $12 million if fully exercised, though that is contingent on investor action. You need to track those warrants closely; they represent contingent future dilution or cash inflow. The company intends to use these net proceeds for developing its oncology therapeutic candidates and general working capital.

Looking ahead, the entire revenue model shifts to potential value creation through successful clinical progression. This is where the real financial upside is anticipated to materialize. The future revenue streams are entirely dependent on successful partnerships and regulatory outcomes:

• Upfront payments from potential licensing deals.
• Milestone payments tied to clinical trial success or regulatory achievements.
• Royalties on future net sales following commercialization by a partner.
• Product sales revenue, though this is contingent on achieving necessary regulatory approval for its candidates like CAPTN-3 (IM1240 and IM1305).

Finance: draft 13-week cash view by Friday.